Published in AIDS Weekly, February 23rd, 2009
A study by the Global HIV Surveillance Program at Abbott (NYSE:ABT) showed significant variation in the ability of diagnostic tests to accurately monitor viral load in patients infected with differing strains, or subtypes, of the HIV virus. The study evaluated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.